Looking at the filing, I can confirm this is Alto Neuroscience, Inc.'s Form 10-Q for the quarterly period ended September 30, 2026, filed November 10, 2026. The ticker is ANRO on the New York Stock Exchange. The filing content provided is primarily the cover page and forward-looking statements section, with limited financial data visible. I will work with what is substantively disclosed.

Alto Neuroscience, Inc. filed a Form 10-Q with the U.S. Securities and Exchange Commission on November 10, 2026, covering the quarterly period ended September 30, 2026.

Key Highlights

  • Shares outstanding: Alto Neuroscience reported 40,110,620 shares of common stock outstanding as of November 5, 2026.
  • Exchange listing: The company's common stock, $0.0001 par value per share, trades on the New York Stock Exchange under the symbol NYSE:ANRO.
  • Company classification: Alto Neuroscience is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company under SEC definitions.
  • Shell company status: According to the filing, the registrant is not a shell company as defined in Rule 12b-2 of the Exchange Act.
  • Extended transition period: The company has not elected to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act.
  • Filing compliance: The registrant confirmed it has filed all reports required during the preceding 12 months and has been subject to filing requirements for the past 90 days.

Alto Neuroscience's Q3 2026 Quarterly Filing: Company Status and Disclosures

Alto Neuroscience, Inc., a Delaware-incorporated clinical-stage company headquartered at 650 Castro Street, Suite 450, Mountain View, CA 94041, submitted its quarterly report for the period ended September 30, 2026. The filing is identified under Commission file number 001-41944, and the company's I.R.S. Employer Identification Number is 83-4210124, according to the filing's cover page.

The company describes itself in the filing as pursuing a Precision Psychiatry Platform, with product candidates targeting identified patient populations. According to the filing, Alto Neuroscience's approach is designed "to reproducibly predict treatment outcomes for product candidates amongst identified patient populations." The company disclosed that it has existing collaboration and licensing agreements and is subject to financial obligations under those arrangements. Research and development activities, including preclinical studies and clinical trials, are described as ongoing elements of the company's operations, according to the quarterly report.

The filing notes that Alto Neuroscience qualifies as an emerging growth company under the JOBS Act and stated that management's forward-looking statements are "based on estimates and assumptions as of the date of this Quarterly Report and are subject to risks and uncertainties." The company directed readers to risk factor disclosures in its Annual Report on Form 10-K for the year ended December 31, 2025, as well as to Item 1A of this quarterly report, for a fuller picture of factors that may affect business and operating results. The company cautioned that investors should not "unduly rely upon" forward-looking statements contained in the filing, as those statements are the company's own and subject to its cautionary language.

What Was Disclosed

Alto Neuroscience, Inc. filed its Form 10-Q for the quarter ended September 30, 2026, disclosing 40,110,620 shares outstanding as of November 5, 2026, its NYSE:ANRO listing, emerging growth company status, and ongoing clinical-stage operations under its Precision Psychiatry Platform.